U.S., Dec. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07261098) titled 'The Efficacy and Safety of ARNI on the Outcome of Advanced Lung Cancer With Concurrent Hypertension' on Nov. 21.
Brief Summary: Despite the rapid development of novel anti-cancer therapeutic agents and ensuing improved prognosis, lung cancer remains the leading cause of cancer-related death globally, of which the majority of mortality could be attributed to advanced lung cancer. Hypertension is frequently diagnosed among patients with advanced lung cancer, either a comorbidity or complication, and is associated with increased incidence of cardiac adverse events, such as heart failure, coronary artery disease, and cardiac arrhythmias,...